Boxer Capital, LLC - Q3 2019 holdings

$1.38 Billion is the total value of Boxer Capital, LLC's 49 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 37.8% .

 Value Shares↓ Weighting
ONCE BuySPARK THERAPEUTICS INC$160,017,000
+160.5%
1,650,000
+175.0%
11.60%
+119.7%
MRTX  MIRATI THERAPEUTICS INC$133,659,000
-24.4%
1,715,5600.0%9.69%
-36.2%
BGNE BuyBEIGENE LTDsponsored adr$113,276,000
+1.5%
925,000
+2.8%
8.21%
-14.4%
IMMU BuyIMMUNOMEDICS INC$92,157,000
+1.2%
6,950,000
+5.8%
6.68%
-14.7%
ODT  ODONATE THERAPEUTICS INC$87,549,000
-29.1%
3,363,3770.0%6.35%
-40.2%
ALLK BuyALLAKOS INC$53,075,000
+157.9%
675,000
+42.1%
3.85%
+117.5%
AMRN NewAMARIN CORP PLCspons adr new$53,060,0003,500,000
+100.0%
3.85%
DBVT  DBV TECHNOLOGIES S Asponsored adr$45,580,000
+4.6%
5,300,0000.0%3.30%
-11.7%
SWTX NewSPRINGWORKS THERAPEUTICS INC$45,006,0002,075,905
+100.0%
3.26%
SRPT NewSAREPTA THERAPEUTICS INC$41,426,000550,000
+100.0%
3.00%
SLDB BuySOLID BIOSCIENCES INC$40,294,000
+101.8%
3,896,872
+12.2%
2.92%
+70.1%
MDCO  MEDICINES CO$37,500,000
+37.1%
750,0000.0%2.72%
+15.6%
ESPR  ESPERION THERAPEUTICS INC NE$35,744,000
-21.2%
975,0000.0%2.59%
-33.5%
GOSS BuyGOSSAMER BIO INC$34,839,000
-16.2%
2,075,000
+10.7%
2.53%
-29.3%
QURE BuyUNIQURE NV$34,062,000
-29.2%
865,400
+40.6%
2.47%
-40.3%
PTCT  PTC THERAPEUTICS INC$33,820,000
-24.8%
1,000,0000.0%2.45%
-36.6%
BMRN NewBIOMARIN PHARMACEUTICAL INC$30,330,000450,000
+100.0%
2.20%
ARGX  ARGENX SEsponsored adr$22,792,000
-19.5%
200,0000.0%1.65%
-32.1%
BCEL  ATRECA INC$21,219,000
-35.0%
1,733,5830.0%1.54%
-45.2%
MIST  MILESTONE PHARMACEUTICALS IN$20,556,000
-31.3%
1,102,1940.0%1.49%
-42.1%
WVE  WAVE LIFE SCIENCES LTD$20,530,000
-21.3%
1,000,0000.0%1.49%
-33.6%
FOLD  AMICUS THERAPEUTICS INC$18,647,000
-35.7%
2,325,0000.0%1.35%
-45.8%
RCKT  ROCKET PHARMACEUTICALS INC$17,079,000
-22.3%
1,466,0510.0%1.24%
-34.5%
APLS NewAPELLIS PHARMACEUTICALS INC$16,863,000700,000
+100.0%
1.22%
PRVL  PREVAIL THERAPEUTICS INC$13,792,000
-7.0%
1,123,1050.0%1.00%
-21.6%
KURA  KURA ONCOLOGY INC$12,815,000
-23.0%
844,7890.0%0.93%
-35.0%
GBT  GLOBAL BLOOD THERAPEUTICS IN$12,130,000
-7.8%
250,0000.0%0.88%
-22.3%
ZGNX NewZOGENIX INC$12,012,000300,000
+100.0%
0.87%
BLU NewBELLUS HEALTH INC NEW$11,342,0001,775,000
+100.0%
0.82%
AKRO BuyAKERO THERAPEUTICS INC$10,977,000
+44.5%
482,495
+21.6%
0.80%
+21.9%
KDMN BuyKADMON HLDGS INC$10,080,000
+32.7%
4,000,000
+8.5%
0.73%
+11.9%
VYGR BuyVOYAGER THERAPEUTICS INC$8,605,000
+216.1%
500,000
+400.0%
0.62%
+166.7%
AVRO NewAVROBIO INC$8,472,000600,000
+100.0%
0.61%
 IMMUNOMEDICS INCcall$7,956,000
-4.4%
600,0000.0%0.58%
-19.3%
LXRX NewLEXICON PHARMACEUTICALS INC$7,525,0002,500,000
+100.0%
0.55%
ACHN NewACHILLION PHARMACEUTICALS IN$7,200,0002,000,000
+100.0%
0.52%
IDYA  IDEAYA BIOSCIENCES INC$6,878,000
-9.6%
764,2520.0%0.50%
-23.7%
LJPC BuyLA JOLLA PHARMACEUTICAL CO$6,820,000
+28.2%
775,000
+34.8%
0.49%
+8.1%
MTNB  MATINAS BIOPHARMA HLDGS INC$6,424,000
-26.4%
10,188,3120.0%0.47%
-37.9%
CBAY  CYMABAY THERAPEUTICS INC$6,400,000
-28.5%
1,250,0000.0%0.46%
-39.7%
MEIP  MEI PHARMA INC$4,894,000
-32.8%
2,913,0910.0%0.36%
-43.3%
SNDX NewSYNDAX PHARMACEUTICALS INC$2,988,000400,000
+100.0%
0.22%
RCUS NewARCUS BIOSCIENCES INC$2,730,000300,000
+100.0%
0.20%
MRSN SellMERSANA THERAPEUTICS INC.$2,656,000
-68.5%
1,680,800
-19.3%
0.19%
-73.4%
KNSA  KINIKSA PHARMACEUTICALS LTD$2,473,000
-37.1%
290,5770.0%0.18%
-47.0%
KALV  KALVISTA PHARMACEUTICALS INC$2,320,000
-47.6%
200,0000.0%0.17%
-55.9%
CLRB  CELLECTAR BIOSCIENCES INC$1,840,000
-8.3%
920,0000.0%0.13%
-22.7%
PRTA NewPROTHENA CORP PLC$624,00079,598
+100.0%
0.04%
NVUS  NOVUS THERAPEUTICS INC$201,000
-38.7%
324,3830.0%0.02%
-46.4%
ExitESPERION THERAPEUTICS INC NEcall$0-250,000
-100.0%
-1.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MIRATI THERAPEUTICS INC32Q3 202355.2%
BEIGENE LTD31Q3 202315.6%
KURA ONCOLOGY INC.24Q3 20214.7%
ROCKET PHARMACEUTICALS INC23Q3 20235.4%
DBV TECHNOLOGIES S A23Q3 20233.9%
MEI PHARMA INC21Q2 20231.4%
SYNDAX PHARMACEUTICALS INC20Q3 20213.1%
GOSSAMER BIO INC19Q3 20234.7%
ODONATE THERAPEUTICS INC18Q1 202212.5%
ESPERION THERAPEUTICS INC NE18Q2 202111.0%

View Boxer Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Boxer Capital, LLC Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
IDEAYA Biosciences, Inc.February 14, 20232,202,8124.6%
Milestone Pharmaceuticals Inc.February 14, 2023698,8612.0%
SpringWorks Therapeutics, Inc.September 19, 20223,421,5415.7%
iTeos Therapeutics, Inc.May 11, 20222,154,0586.1%
Atreca, Inc.February 14, 20222,202,3337.2%
Biomea Fusion, Inc.February 14, 20221,188,4054.1%
Cabaletta Bio, Inc.February 14, 2022540,0001.9%
CymaBay Therapeutics, Inc.February 14, 2022? ?
DBV Technologies S.A.February 14, 20221,067,2991.9%
Elevation Oncology, Inc.February 14, 2022872,7803.8%

View Boxer Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-22
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G2024-02-12
42024-02-08
SC 13D/A2024-02-08
42024-01-25
SC 13D/A2024-01-25
SC 13G2024-01-18
SC 13D/A2023-12-18

View Boxer Capital, LLC's complete filings history.

Compare quarters

Export Boxer Capital, LLC's holdings